Trial reportAntimicrobial agents and chemotherapy2026
Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19.
Trial report in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.